In inflammatory CNS conditions such as multiple sclerosis (MS), current options to treat clinical relapse are limited, and more selective agents are needed. Disruption of the bloodbrain barrier (BBB) is an early feature of lesion formation that correlates with clinical exacerbation, leading to edema, excitotoxicity, and entry of serum proteins and inflammatory cells. Here, we identify astrocytic expression of VEGF-A as a key driver of BBB permeability in mice. Inactivation of astrocytic Vegfa expression reduced BBB breakdown, decreased lymphocyte infiltration and neuropathology in inflammatory and demyelinating lesions, and reduced paralysis in a mouse model of MS. Knockdown studies in CNS endothelium indicated activation of the downstream effector eNOS as the principal mechanism underlying the effects of VEGF-A on the BBB. Systemic administration of the selective eNOS inhibitor cavtratin in mice abrogated VEGF-A-induced BBB disruption and pathology and protected against neurologic deficit in the MS model system. Collectively, these data identify blockade of VEGF-A signaling as a protective strategy to treat inflammatory CNS disease.
microinjection of an IL-1β vector, AdIL-1 (30, 31) , into cortical gray matter. In uninjected or empty vector-injected cortices of 12-week-old mice, GFAP immunoreactivity was low in all genotypes, and VEGF-A was not detected (Supplemental Figure 1 , A and B; supplemental material available online with this article; doi:10.1172/JCI60842DS1). Conversely, AdIL-1-injected cortices exhibited hypercellular lesions containing GFAP + reactive astrocytes, with numbers maximal at 7 days postinduction (dpi) (Supplemental Figure 1, A and B) . In controls at 7 dpi, lesions were also positive for VEGF-A, which localized to GFAP + cells (Figure 1 , (10 7 pfu) was microinjected into cortical gray matter of 12-week-old GfapCre:Vegfa fl/fl mice and littermates (n = 21, at least 4 per genotype); animals were sacrificed at 7 dpi, based on time course studies (see Supplemental Figures 1 and 2) ; and lesions were stained and examined to determine the number of GFAP + and VEGF-A + cells. Data are representative of 3 independent experiments. In G, individual channels from sections of the merged images are shown at right. See Supplemental Figure 1D for higher-magnification images of VEGF-A + GFAP + cells. Scale bars: 50 μm (C and G). *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA plus Bonferroni test. Figure 3C ). Inflammation paralleled BBB disruption and was maximal at 7 dpi. However, T cell numbers were reduced in lesions in GfapCre:Vegfa fl/fl mice (Figure 3 , B and C), and no CD19 + cells were detected, compared with 1,554 ± 294 cells/mm 3 in Vegfa fl/fl controls. Numbers of CD11b + cells and GFAP + reactive astrocytes were unchanged ( Figure 3 , A and B, and Figure 1F ).
We reasoned that BBB integrity might directly limit lymphocyte entry into the CNS in GfapCre:Vegfa fl/fl mice. Alternatively, peripheral lymphocytes might be reduced, or CNS expression of adhesion molecules, chemokines, or MMPs might be restricted. However, we found that peripheral lymphocyte numbers were normal in naive GfapCre:Vegfa fl/fl animals, and numbers of T and B cells in peripheral lymphoid organs were identical to those of other genotypes (Supplemental Figure 3, A-D) . Moreover, AdIL-1 lesions in GfapCre:Vegfa fl/fl animals displayed normal endothelial immunoreactivity for VCAM-1, ICAM-1, CXCL10, and CXCL12 ( Figure 3 , D and E) and normal CNS induction of MMP-9 and MMP-3 ( Figure  3 , F and G). In addition, in CNS MVEC cultures, IL-1β strongly induced VCAM-1, ICAM-1, CXCL1, CXCL8, CXCL10, and CCL2 and the cytokines IL-6 and TNF-α, but none of these factors was VEGF-A responsive ( Figure 3 , H and I).
We compared these results with data from animals receiving therapies currently used in MS patients in relapse, for example, 50 mg/ml methylprednisolone (MP) (32) . In mice receiving MP prior to AdIL-1, BBB breakdown, lymphocyte infiltration, and VEGF-A immunoreactivity were restricted ( Figure 3 , J and K). However, these effects were part of a more extensive cohort of changes, including reduced numbers of reactive astrocytes ( Figure 3J ) and inhibition of endothelial adhesion molecule expression ( Figure 3K ).
These results showed that lymphocyte infiltration into AdIL-1-induced inflammatory lesions was restricted in GfapCre:Vegfa fl/fl mice, which correlated with reduced BBB disruption, but was not associated with wider immune suppression, such as was seen in steroid-treated animals. These data were compatible with previous work showing that BBB breakdown facilitates lymphocyte entry into the CNS parenchyma (21) .
Reduced neuropathology in focal gray and white matter lesions in GfapCre:Vegfa fl/fl mice. We examined changes in neuropathology in GfapCre:Vegfa fl/fl mice ( Figure 4 and Supplemental Figure 4) . The number and organization of cortical NeuN + neurons was normal in unchallenged GfapCre:Vegfa fl/fl adults, and no neuronal apoptosis was observed (Supplemental Figure 4A) . In controls, we observed areas of neuronal loss in cortical AdIL-1 lesions at 7 dpi, in areas of inflammation and BBB disruption ( Mice (8-week-old males, at least 10 per group) were sensitized with encephalitogenic myelin oligodendrocyte glycoprotein in CFA (MOG /CFA), and clinical deficit was evaluated using a 5-point paradigm (35) . Ascending paralysis was observed from 7 dpi, and the deficit increased in Vegfa fl/fl controls until 19 days, when clinical score stabilized at a mean of 2.84, representing severe hindlimb weakness approaching complete paralysis ( Figure 5A ). GfapCre:Vegfa fl/fl mice showed much milder signs, which reached a plateau at 16 days at a mean of 1.21, indicative of a limp tail. The divergence in scores reached significance at 13, 14, and 17-21 dpi (i.e., through the end of the experiment; Figure 5A ). Examination of peak severity in each mouse showed that 53% of controls, compared with 1 GfapCre:Vegfa fl/fl mouse (10%), displayed complete hindlimb paralysis or worse during the study (score ≥ 3) ( Figure 5B ). Mortality or severe paralysis requiring euthanasia (score ≥ 4) occurred in 33% of controls compared with 0 GfapCre:Vegfa fl/fl mice ( Figure 5B ).
The reduction of clinical disease in GfapCre:Vegfa fl/fl mice was associated with decreased tissue damage ( Figure 5 , C-K). In spinal cords of controls at 21 dpi, typical pathology of EAE was observed, including astrogliosis ( Figure 5C ), BBB breakdown ( Figure 5D ), inflammatory cell infiltration ( Figure 5E ), and multifocal demyelination and oligodendrocyte loss ( Figure 5F ). VEGF-A was strongly expressed in lesions in controls, localizing to GFAP + reactive astrocytes, but VEGF-A + cells were almost com- In adults, HIF-1α was not observed in naive cortices, but was strongly expressed in AdIL-1-induced lesions in controls at 7 dpi, where it localized to nuclei of GFAP + reactive astrocytes ( To confirm the relevance of VEGFR2 signaling in vivo, we coinjected 20 ng VEGF-A or vehicle with either VEGFR2-blocking antibody or IgG control (2 μg) into cortices of 12-week-old C57BL/6 mice (n = 3 per group). Animals were sacrificed at 24 hours. VEGF-A caused disruption of endothelial CLN-5 and OCLN and BBB breakdown, but VEGFR2 blockade inhibited these events ( Figure  7 , C and D). Thus, the effects of VEGF-A on BBB junction components were VEGFR2 dependent.
Effects of VEGF-A on CLN-5 are mediated via eNOS. Treatments to inhibit astrocytic VEGF-A production or binding to endothelial VEGFR2 would require entry to the CNS parenchyma, across the BBB. In contrast, agents targeting VEGF-A signaling in CNS endothelium could enter the cell from the circulation via the luminal surface, and so could be delivered systemically. We therefore analyzed signaling pathways underlying the effects of VEGF-A in CNS endothelial cells.
VEGFR2 activates 4 pathways in endothelium ( Figure 7A ): PLCγ, which stimulates MEK-MAPK; Shb activation of PI3K-Akt; TSAd and Src; and p38 (39) . Additionally, VEGF-A activates eNOS via PLCγ and PI3K. In human CNS MVECs, VEGF-A induced phosphorylation of the PI3K pathway transcription factor GSK3 (S21/9), MEK kinase p44/42 (T202/Y204), and Src (Y416). Responses of GSK3 and p44/42 peaked at 16 hours, whereas strong Src phosphorylation was seen at both 6 and 16 hours (Supplemental Figure 6 , B and C). VEGF-A also induced phosphorylation of eNOS (S1177), which increased progressively to 24 hours (Supplemental Figure 6 , B and C). No activation of p38 (T180/Y182) was observed.
In pharmacologic studies, PLCγ1 blockade using 5 μM U73122 inhibited VEGF-A downregulation of CLN-5, whereas inhibition of Src kinase, p44/42, or PI3K had no effect ( Figure 7E ). These findings implicated PLCγ, but showed that it was not acting via MAPKs, and so we focused on eNOS, the other PLCγ effector in VEGF-A signaling. To inhibit eNOS in CNS MVEC cultures, we initially used cavtratin, a cell-permeable fusion protein that selectively blocks eNOS enzymatic activity via protein-protein interaction without affecting other forms of NOS (40) (41) (42) . Importantly, VEGF-A disruption of CLN-5 was abrogated by pretreatment with 2 μM cavtratin ( Figure 7F ). VEGF-A downregulation of CLN-5 in human CNS MVECs was also specifically inhibited by siRNA silencing of eNOS expression ( Figure 7G ). Interestingly, higher concentrations of other NOS inhibitors, including 100 μM l-N5-(1-iminoethyl) ornithine,dihydrochloride (l-NIO) (43), gave similar results in endothelial cells (Supplemental Figure 6D) . To test inhibitor specificity, we examined the effects on iNOS expression and NO release in LPS-stimulated macrophages or astrocytes treated with IL-1β plus IFN-γ. Compatible with previous findings (40) , and in contrast to its marked effects in endothelial cells, cavtratin had no effect on NO production in these systems, whereas all other inhibitors tested significantly reduced nitrite levels (Supplemental Figure 6E) . Collectively, these data suggest cavtratin inhibition of endothelial VEGF-A signaling as a potential therapeutic avenue by which to inhibit BBB breakdown in vivo.
Peripherally delivered cavtratin abrogates VEGF-induced BBB disruption and pathology. Within the adult CNS, eNOS immunoreactivity localized to endothelial cells (Supplemental Figure 6F) . To test the effect of eNOS blockade on the effects of VEGF-A in vivo, we administered 2.5 mg/kg cavtratin or vehicle i.p. to 12-week-old C57BL/6 mice (3 per group), then 30 minutes later microinjected 60 ng VEGF-A or control into cortical layers IV and V ( Cavtratin protects against paralysis in EAE. We tested the effect of cavtratin administration on clinical disease and CNS damage in EAE, comparing the results with the phenotype seen in GfapCre:Vegfa fl/fl mice ( Figure 8 , compare with Figure 5 ). Mice (8-week-old male C57BL/6, 10 per group) were sensitized with MOG 35-55 /CFA (35), then treated daily for 7 days from the onset of weight loss (>10% BW) with 2.5 mg/kg/d cavtratin or vehicle i.p., and neurological signs were evaluated as described previously (35) .
Weight loss occurred -and therapy was concurrently initiatedat 7 dpi, and ascending paralysis was first observed 24 hours later, with severity in controls increasing until 16 days, when neurologic deficit reached a plateau at a mean of 3.22, indicative of complete hindlimb paralysis plus mild forelimb weakness ( Figure 8A ). Signs in cavtratin-treated mice were much less severe, and peaked at 17 days at a mean of 1.78 (limp tail with mild hindlimb weakness). The difference in scores was significant at 12-16 days ( Figure 8A ). Comparison of peak clinical severity in each animal was even more revealing: almost all controls (90%), but less than half of cavtratin-treated mice (40%), displayed complete hindlimb paralysis or worse (score ≥ 3) ( Figure 8B ). In controls, mortality or severe paralysis requiring euthanasia (score ≥ 4) was 40%, compared with 10% in the cavtratin-treated group ( Figure 8B ). Neuropathology was also decreased in cavtratin-treated mice (Figure 8, C-F) . CLN-5 immunoreactivity was rescued and BBB disruption and inflammatory cell infiltration inhibited (Figure 8 , C-E), and myelin and oligodendrocytes were preserved (Figure 8, C and F) .
These findings were compatible with our EAE data from GfapCre:Vegfa fl/fl mice and showed that cavtratin treatment during the acute clinical phase of a model of MS protected against paralysis and neuropathology. Our results therefore suggested blockade of endothelial VEGF-A signaling as an avenue by which to restrict neurological deficit and tissue damage.
Discussion
In this study, we defined a therapeutic approach for inflammatory CNS disease using inhibition of BBB breakdown to restrict clinical severity and permanent pathology, which we believe to be novel. This approach is based on our identification of a mechanism whereby reactive astrocytes mediate disruption of BBB integrity ( Figure 9 ). Our findings showed that the angiogenic factor VEGF-A was an important effector used by reactive astrocytes to drive vascular permeability and CNS damage in acute inflammatory lesions. We identified CLN-5 and OCLN as targets of VEGF-A action in cortical and spinal cord endothelial cells and showed that both proteins, and BBB breakdown, were rescued in inflammatory and demyelinating plaques in the CNS of GfapCre:Vegfa fl/fl mice, in which VEGF-A inactivation was targeted to reactive astrocytes. We further identified the downstream effector eNOS as mediating the effects of VEGF-A on CLN-5 and the BBB. Finally, we showed that treatment with the selective eNOS inhibitor cavtratin during the acute clinical phase of EAE protected against paralysis and pathology, similar to the EAE phenotype seen in GfapCre:Vegfa fl/fl mice. Collectively, our findings suggested blockade of endothelial VEGF-A signaling as an avenue by which to restrict clinical severity and tissue damage in inflammatory CNS conditions ( Figure 9 ).
Recent work has examined the role of pericytes in BBB maintenance (6-8), but earlier studies also define important astrocytic functions at the BBB (9, 10), and it was on the latter cell type that our work here focused. Astrocytes respond to CNS inflammation or injury with a graded spectrum of molecular expression, hypertrophy, and, in severe cases, scarring (45) . These changes, called reactive astrogliosis, affect surrounding neural and non-neural cells beneficially or detrimentally, depending on the pathways driving the astroglial phenotype (34, 46, 47) . Studies have identified astrocytes as regulators of BBB induction and maintenance (9-11) and have implicated astrogliosis, particularly induced by IL-1, as a driver of both BBB breakdown and repair (10, 12, 48) . The mediators producing the effects of reactive astrocytes are incompletely characterized, and our data revealed VEGF-A as an important astrocyte-derived inducer of BBB disruption and pathology in vivo. Although VEGF-A-induced vascular permeability has previously been implicated in pathogenesis of disorders, including myocardial infarction, CNS hypoxia/reperfusion injury, and tumor growth and metastasis (49), and we and others have previously speculated on its role in BBB breakdown (12, 26) , this study is the first to our knowledge to show the significance of astrocyte-derived VEGF-A in lesion pathogenesis and generation of clinical deficit in models of CNS inflammatory disease.
The BBB uses endothelial tight junctions to generate a physical barrier, allowing control of transcellular molecular trafficking via endothelial transporters and channels (1, 2) . Disruption of the endothelial tight junction transmembrane proteins CLN-3, CLN-5, and OCLN correlates with BBB opening in EAE (4, 12) , and downregulation of CLN-5 is linked to BBB breakdown in glioblastoma multiforme (50) and models of amyotrophic lateral sclerosis (51) and viral encephalomyelitis (52) . Redistribution of CLN-5 and OCLN away from the cell membrane has also been implicated in BBB disruption in inflammatory models (53) . Importantly, our data showed that VEGF-A downregulated endothelial expression of both CLN-5 and OCLN, and we observed rescue of both proteins, and BBB integrity, in CNS inflammation in GfapCre:Vegfa fl/fl mice. To quantify BBB breakdown, we measured extravasation of fibrinogen, albumin, and Ig. In the healthy CNS, these proteins are confined to the vasculature, and their leakage into the parenchyma has been widely used as an endogenous marker of BBB disruption (8, 11, 17) . CNS entry of Igs and fibrinogen has also been linked to exacerbation of inflammation and demyelination and to inhibition of repair (17) (18) (19) , suggesting relevance to lesion pathogenesis.
Our studies in vivo also showed that reduced BBB disruption in GfapCre:Vegfa fl/fl mice was accompanied by mitigation of lymphocyte infiltration and implicated BBB integrity as an important mechanism underlying this effect. Whereas BBB breakdown was restricted in AdIL-1-induced lesions in GfapCre:Vegfa fl/fl mice, we found that endothelial adhesion molecule and chemokine expression and CNS induction of MMPs were the same as in other genotypes. VCAM-1 and ICAM-1 (54), as well as CC and CXC chemokines (55) , are important in driving inflammatory cell transmigration, whereas MMPs facilitate entry through the glia limitans and infiltration into the CNS parenchyma (56) . Using the focal, directly induced AdIL-1 model in GfapCre:Vegfa fl/fl mice allowed us to selectively examine the effect of VEGF-Ainduced BBB breakdown on lymphocyte entry while retaining these other important variables. Critically, we also found in these experiments and in EAE studies that inhibition of BBB breakdown and leukocyte infiltration in GfapCre:Vegfa fl/fl mice was associated with restriction of gray and white matter pathology and with reduced clinical paralysis. Thus, our data implicate inhibition of VEGF-A signaling as a protective avenue in patients with CNS inflammation.
The transcription factor HIF-1α induces VEGF-A during development (36) and is induced transcriptionally by IL-1β in astrocytes, suggesting relevance to hypoxic/ischemic and inflammatory disease (23) . However, although these data suggest HIF-1α as a potential route to inactivation of astrocytic VEGF-A, conditional GfapCre:Hif1a fl/fl mice displayed little effect on VEGF-A expression or BBB disruption in AdIL-1 lesions. These findings indicate that mechanisms regulating VEGF-A in embryogenesis and inflammation are likely distinct. However, our data do not invalidate roles in inflammatory lesion pathogenesis for other members of the family, for example, HIF-2α, which has previously been implicated as a regulator of astrocytic VEGF-A production in VHL-deficient mice and in oxygen-induced retinopathy (57) . In addition, our findings focused on inflammation and did not address astrocytic responses to hypoxic/ischemic injury. The results of our analyses of endothelial VEGF-A signaling were more directly translational, identifying a therapeutic avenue by which to inhibit BBB breakdown. In CNS MVEC cultures, we found that VEGF-A downregulation of CLN-5 and OCLN occurred via VEGFR2 signaling through PLCγ and its effector, eNOS. Notably, targeting events within the endothelial cell allows for systemic delivery and avoids issues with CNS access, and our studies examining eNOS blockade in vivo validated this approach in a therapeutic setting. Tonic eNOS activity controls vascular tone and leukocyte trafficking in the resting state, whereas the activated form drives permeability and extravasation in disease (58) . The phenotype of eNOS mutants combines inactivation of the tonic and activated forms and produces complex findings in EAE and carrageenaninduced inflammation (59) . Understanding the translational potential of eNOS has been facilitated by development of selective inhibitors, notably cavtratin, a cell-permeable recombinant consisting of the eNOS-binding domain of caveolin-1 coupled to the homeodomain of Drosophila antennapedia (40) (41) (42) . Cavtratin binds to eNOS via the caveolin-1 scaffolding domain, specifically inhibiting its enzymatic activity via protein-protein interaction (40, 42) . Previous work has also shown that cavtratin does not block activity of other forms of NOS (40) (41) (42) , and our experiments in vitro support these results ( Figure 7F and Supplemental Figure 6E ). Cavtratin reduces tumor microvascular permeability and progression (41)
Figure 6
GfapCre:Hif1a fl/fl mice show normal VEGF-A expression and BBB opening in inflammatory lesions. (A) Primary human astrocytes were treated with 10 ng/ml IL-1β, TGF-β1, or LPS for the indicated times, and HIF-1α induction was examined by immunoblot. (B) Human astrocytes were treated with 10 ng/ml IL-1β or vehicle for 24 hours. In IL-1β-treated cultures, HIF-1α localized to astrocytic nuclei (inset; enlarged 2-fold). Results in A and B are typical of data from 3 separate cultures of human astrocytes from different brains. (C-G) AdIL-1 was microinjected into cortical gray matter of 12-week-old GfapCre:Hif1a fl/fl mice and littermate controls (n = 4 per genotype), and animals were sacrificed at 7 dpi. Immunostaining and morphometry were performed for (C and D) HIF-1α, (C and E) VEGF-A, and (F and G) fibrinogen (a measure of BBB breakdown) and CLN-5. In D, representative cells (arrows) are shown enlarged 2-fold in the insets (arrowheads). Results in C-G are representative of 3 independent experiments. Scale bars: 30 μm (B, D, and E); 40 μm (G). **P < 0.01, ANOVA plus Bonferroni test.
and restricts edema in inflammatory models without influencing systemic hemodynamics (40) . In CNS MVECs, our results showed that cavtratin matched the effect of eNOS siRNA in abrogating VEGF-A-induced downregulation of CLN-5 and OCLN, and its administration in vivo produced a phenotype similar to that seen in GfapCre:Vegfa fl/fl mice in terms of blockade of BBB breakdown, lymphocyte infiltration, and tissue damage in inflammatory lesions. Importantly, treatment in the acute stages of EAE was also protective, suggestive of relevance to human disease.
These data suggest further studies to investigate roles of VEGF-A and eNOS in other inflammatory CNS conditions. For example, blocking the pathway might be effective in preventing CNS entry of extrathecally produced autoantibodies in diseases such as neuromyelitis optica. These approaches may also represent a means by which to examine the role of BBB permeability in disorders characterized by slowly accumulating tissue damage accompanied by low-grade inflammation and BBB leakage, such as primary or secondary progressive MS (16) . It might also be interesting to combine inhibition of inducers of BBB disruption, such as VEGF-AeNOS and MMPs, with activation of pathways promoting barrier formation and/or repair, such as Shh signaling (11), for potentially additive or synergistic outcomes.
Methods
Cytokines and growth factors. Human IL-1β, PlGF, and VEGF-C and mouse VEGF165 and VEGF121 were from Peprotech. Human VEGF-A, IFN-γ, TGF-β1, and IL-6 were from R&D Systems. Human and mouse VEGF-A were used at 1-100 ng/ml, human VEGF165 and VEGF121 at 1-20 ng/ml, and other factors at 10 ng/ml.
Expression constructs. The adenoviral IL-1β vector AdIL1 and control AdDL70 were gifts from J. Gauldie (McMaster University, Hamilton, Ontario, Canada; ref. 30) . Previous work has shown that intracerebral microinjection of 10 7 pfu AdIL1, but not empty vector, induces inflammation, astro-and microgliosis, and BBB breakdown at 8-14 dpi (31) .
Antibodies. Anti-CLN-5 (mouse), anti-OCLN, anti-cingulin, anti-ZO-1 (rabbit), anti-GFAP (rat), and anti-fluoromyelin were from Invitrogen.
Anti-VEGF-A (rabbit) was from Santa Cruz Biotech. Anti-albumin (sheep) and anti-CD3 were from Abcam. Anti-fibrinogen (rabbit) and anti-FVIIIR (mouse) were from Dako. Antibodies for phosphorylated versus total eNOS, p44/42, p-GSK3, PLCγ, and Src and for cleaved caspase-3 (rabbit) were from Cell Signaling. Mouse anti-eNOS was from BD. Anti-CD4, anti-CD19, anti-CXCL10, anti-CXCL12, anti-VEGFR2, anti-VCAM-1, and anti-ICAM-1 (rat or rabbit) were from eBioscience. Anti-HIF-1α was from ThermoScientific. Antibodies for NeuN and Olig2 were from Millipore, and Sternberger mouse anti-MBP was from Covance.
Inhibitors. Anti-VEGFR2 blocking antibody and control IgG (10 ng/ml) were from R&D Systems. The PLCγ1 inhibitor U73122 and inactive analog U73343 (both 5 μM), Src kinase inhibitor PP2 (3 μM), eNOS inhibitor cavtratin (2 μM in vitro, 2.5 mg/kg in vivo) (40) , NOS inhibitors l-NIO and l-NAME (both 100 μM) (43) , and DPI (50 μM) were from EMD. The p44/42 inhibitor U0126 (10 μM) and PI3K inhibitor LY294002 (20 μM) were from Cell Signaling. Efficacy and specificity were confirmed by blotting with phosphospecific antibodies (Supplemental Figure 6) , and toxicity was monitored using TUNEL and LDH assays (Promega). Human CNS MVEC cultures were transferred into medium with inhibitor, homolog, or vehicle for 2 hours, then VEGF-A was added and protein harvested 1-24 hours later.
Mice. GfapCre mice (generated in the M.V. Sofroniew lab) express Cre recombinase under a 15-kb promoter cassette containing the murine Gfap gene and all introns and regulatory elements (28) . Cre expression is astrocyte specific except in areas of adult neurogenesis, where it is also observed in some neural progenitors (28) . Vegfa fl mice were generated in the N. Ferrara lab and have been reported previously (29) . Stereotactic microinjection. Mice (12 weeks of age, 4 per genotype per condition per time point, unless otherwise indicated) were anesthetized and placed into a stereotactic frame (Kopf Instruments). For injection of AdIL1 or AdDL70 control (10 7 pfu) or mouse VEGF164 (60 ng, in 3 μl of PBS/BSA vehicle) or vehicle into layers IV and V of cortical gray matter, coordinates used were y of 1 mm caudal to Bregma, x of 2 mm (left), and z of 1.5 mm (12) . For induction of focal demyelination in corpus callosum, 1.5 μl 1% lysolecithin was delivered at y of 5.5 mm anterior to Lambda, x of 1 mm (left), and z of 2 mm (33). Mice were harvested by perfusion with 4% paraformaldehyde at 24 hours to 14 dpi.
EAE. Mice (8-week-old males on the C57BL/6 background, at least 10 per group) were immunized s.c. with 300 μg MOG35-55 (Invitrogen) in 200 μl CFA containing 300 μg/ml Mycobacterium tuberculosis H37Ra (Difco) in the dorsum. Mice received 500 ng pertussis toxin i.p. at 0 and 2 dpi. Disease was scored as follows: 0, no symptoms; 1, floppy tail; 2, hindlimb weakness; 3, hindlimb paralysis; 4, fore-and hindlimb paralysis; 5, death (35) . Immunohistochemistry. Embedding and immunostaining were as previously described (12) unless otherwise indicated. For claudins, prior to blocking, sections were soaked in EDTA (pH 8; 100°C). For OCLN, VEGF-A, CXCL12, CD4, and CD19, sections were treated with 0.5 mg/ml protease XIV (Sigma-Aldrich) at 37°C for 5 minutes. For VEGFR2, sections were treated with 1% SDS for 5 minutes at room temperature. Primary antibodies were used at 1:100 except CLN-5 (1:50), fibrinogen (1:1,000), and albumin (1:1,000). Fluoromyelin was used at 1:200 in final wash. Samples were examined using a Leica Microsystems confocal microscope, and stacks were collected with z of 1 μm.
Morphometric analysis. Morphometric analyses were carried out using NIH ImageJ software. Pixels positive for CD11b, CLN-5, OCLN, fibrinogen, albumin, VCAM-1, ICAM-1, CXCL10, and CXCL12 immunoreactivity, or cells positive for CD4, CD19, GFAP, VEGF-A, HIF-1α, or Olig2 were counted by a blinded observer in projections from cortical sections with the same number of images from at least 4 animals per condition per genotype per time point and 4 age-and sex-matched normal controls (unless otherwise indicated): at least 5 random ×20 fields in 5 sections per animal. Neuronal and myelin loss were quantified using previously published analyses (35); NeuN -or MBP -pixels were subtracted from the total in each field in matched projections at ×20 magnification using ImageJ software, and data were converted to absolute area.
Cell culture. Primary human fetal astrocyte cultures were established from 3 different brains, as described previously (23) . Primary human CNS MVECs were purchased from Cell Systems Inc. and cultured in complete serum-containing medium. Primary mouse cortical MVECs and spinal cord MVEC cultures were established as described previously (12) .
siRNA. Human MVEC cultures were nucleofected with siRNA for eNOS or other components of VEGF-A signaling, with nontargeting control siRNA, or with transfection reagent alone (sham) using Amaxa nucleofector program T05 (Amaxa), then treated with VEGF-A. At 24 hours, protein extracts were harvested and subjected to immunoblotting
Figure 8
Reduced clinical severity and neuropathology of EAE in cavtratin-treated mice. Mice (8-week-old male C57BL/6, 10 per group) were sensitized with MOG35-55/CFA, then from onset of weight loss (7 dpi) treated for 7 days with 2.5 mg/kg/d i.p. cavtratin or vehicle. (A and B) Disease was scored using a 5-point paradigm (35) and plotted (A) as a function of time and (B) by peak score. (C) Lumbar spinal cord sections were subjected to immunostaining at 21 dpi to assess BBB breakdown (top) as well as demyelination and oligodendrocyte loss (bottom). (D-F) Morphometry of (D) fibrinogen (a measure of BBB breakdown) and CLN-5, (E) CD45 (a measure of inflammatory cell infiltration), and (F) Olig2 and demyelination (assessed by fluoromyelin). These findings resembled the phenotype of EAE in GfapCre:Vegfa fl/fl mice (see Figure 5 ). Scale bars: 50 μm (C, top); 150 μm (C, bottom); 40 μm (C, insets). *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA plus Bonferroni test (A) or Student's t test (B and D-F) . Data are representative of 3 independent experiments.
for CLN-5 and targeted and nontargeted control signaling molecules to confirm siRNA efficacy and specificity.
Immunoblotting. SDS-PAGE and blotting were carried out as reported previously (23) . Nonsaturated films were scanned using a Canon LiDE scanner, band pixel density was measured using ImageJ software and standardized to loading control, and fold change was calculated.
Immunocytochemistry. Cultures were fixed and stained as described previously (12) . For claudins, cells were fixed in 95% ethanol at 4°C for 30 minutes, then in 1:1 methanol/acetone for 1 minute at room temperature. Primary antibodies were used at 1:100, except CLN-5 (1:50). Cultures were examined as described above, and stacks were collected with z of 0.5 μm.
ELISA. Multiplex ELISA kits for human CXCL1, CXCL8, CXCL10, CCL2, IL-6, TNF-α, and VEGF-A were from Millipore and R&D Systems.
Statistics. Data represent mean ± SEM. For multiple comparisons, 1-way ANOVA plus Bonferroni post-test was used. 2-tailed Student's t test was used to compare 2 groups of matched samples. A P value less than 0.05 was considered significant.
Study approval. Animal studies were approved by the MSSM Institutional Animal Care and Use Committee. Experiments in human cell cultures were approved by the MSSM Institutional Review Board. As verified by the MSSM Institutional Review Board and in line with local, state, and federal regulations, informed consent was not required for the use of cell cultures in the present study; the cultures have exempt status since they are prepared from postmortem deidentified tissue samples.
Figure 9
Proposed mechanism underlying BBB disruption in CNS inflammatory lesions. The inflammatory cytokine IL-1β is produced early in lesion pathogenesis by mononuclear phagocytes and binds to its receptor on astrocytes adjacent to CNS microvessels, leading to Vegfa induction. VEGF-A released from the astrocyte binds to VEGFR2 on CNS MVECs, activating eNOS-dependent downregulation of Cln5 and Ocln and leading to disruption of endothelial tight junctions and BBB breakdown. These events facilitate parenchymal entry of autoantibodies, plasma proteins, and lymphocytes, leading to inflammation, edema, and excitotoxicity and exacerbation of neuropathology. How these astrocyte-driven effects interact with pericyte effects at the BBB is not known.
